Madrigal Pharmaceuticals, Inc. (MDGL) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $523.00 (-0.56%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 14, 2026 | Andrea Tan | Goldman Sachs | $571.00 | +9.2% |
| Jan 6, 2026 | Andy Chen | Wolfe Research | $579.00 | +10.7% |
| Dec 19, 2025 | Yasmeen Rahimi | Piper Sandler | $900.00 | +72.1% |
| Nov 20, 2025 | Jay Olson | Oppenheimer | $650.00 | +24.3% |
| Oct 10, 2025 | Jay Olson | Oppenheimer | $590.00 | +12.8% |
| May 2, 2025 | Edward Nash | Canaccord Genuity | $420.00 | -19.7% |
| May 29, 2024 | Yasmeen Rahimi | Piper Sandler | $336.00 | -35.8% |
| May 9, 2024 | Ed Acre | H.C. Wainwright | $390.00 | -25.4% |
| Mar 19, 2024 | Liisa Bayko | Evercore ISI | $405.00 | -22.6% |
| Mar 15, 2024 | Eliana Merle | UBS | $410.00 | -21.6% |
| Mar 15, 2024 | Akash Tewari | Jefferies | $400.00 | -23.5% |
| Mar 15, 2024 | Ed Acre | H.C. Wainwright | $425.00 | -18.7% |
| Mar 15, 2024 | Jonathan Wolleben | JMP Securities | $397.00 | -24.1% |
| Mar 15, 2024 | Mayank Mamtani | B.Riley Financial | $270.00 | -48.4% |
| Aug 6, 2021 | Matthew Luchini | BMO Capital | $111.00 | -78.8% |
| May 20, 2021 | Andrea Tan | Goldman Sachs | $195.00 | -62.7% |
| May 6, 2021 | Derek Archila | Wells Fargo | $130.00 | -75.1% |
Top Analysts Covering MDGL
MDGL vs Sector & Market
| Metric | MDGL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.25 | 2.42 |
| Analyst Count | 8 | 8 | 18 |
| Target Upside | +26.9% | +16187.2% | +19.5% |
| P/E Ratio | -40.21 | 3.83 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $368M | $387M | $410M | 4 |
| 2026-12-31 | $415M | $437M | $463M | 7 |
| 2027-03-31 | $384M | $405M | $429M | 4 |
| 2027-06-30 | $440M | $463M | $491M | 6 |
| 2027-09-30 | $511M | $538M | $570M | 4 |
| 2027-12-31 | $611M | $644M | $682M | 7 |
| 2028-12-31 | $2.98B | $2.98B | $2.98B | 11 |
| 2029-12-31 | $3.62B | $3.96B | $4.34B | 5 |
| 2030-12-31 | $4.55B | $4.97B | $5.45B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.22 | $-0.21 | $-0.20 | 1 |
| 2026-12-31 | $0.76 | $0.81 | $0.88 | 1 |
| 2027-03-31 | $-0.39 | $-0.36 | $-0.34 | 1 |
| 2027-06-30 | $1.52 | $1.63 | $1.75 | 1 |
| 2027-09-30 | $3.85 | $4.13 | $4.44 | 1 |
| 2027-12-31 | $7.11 | $7.62 | $8.20 | 1 |
| 2028-12-31 | $16.41 | $31.28 | $47.05 | 11 |
| 2029-12-31 | $45.76 | $51.53 | $57.99 | 4 |
| 2030-12-31 | $64.62 | $72.76 | $81.88 | 4 |
Frequently Asked Questions
What is the analyst consensus for MDGL?
The consensus among 8 analysts covering Madrigal Pharmaceuticals, Inc. (MDGL) is Buy with an average price target of $656.00.
What is the highest price target for MDGL?
The highest price target for MDGL is $900.00, set by Yasmeen Rahimi at Piper Sandler on 2025-12-19.
What is the lowest price target for MDGL?
The lowest price target for MDGL is $111.00, set by Matthew Luchini at BMO Capital on 2021-08-06.
How many analysts cover MDGL?
8 analysts have issued ratings for Madrigal Pharmaceuticals, Inc. in the past 12 months.
Is MDGL a buy or sell right now?
Based on 8 analyst ratings, MDGL has a consensus rating of Buy (2.12/5) with a +26.9% upside to the consensus target of $656.00.
What are the earnings estimates for MDGL?
Analysts estimate MDGL will report EPS of $-0.21 for the period ending 2026-09-30, with revenue estimated at $387M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.